葛兰素史克Glaxosmithkline（GSK）2025年第三季度产品线资产及临床试验报告「LSE」（英文版）（88页）.pdf

1、Pipeline assets and clinical trials appendixQ3 2025Infectious disease2ContentsInnovation:Pipeline growthClinical trialsRespiratory,Immunology and Inflammation(RI&I)OncologyHIVInfectious DiseasesInfectious disease3Innovation:Pipeline growthOverview of potential new vaccines and medicinesHIVOncologyIn

2、fectious DiseasesGlossaryInnovation:Pipeline growthRI&IRI&IOncologyHIVInfectious DiseasesPhase III/RegistrationPhase III/Registration16)depemokimab(GSK3511294)Long-acting anti-IL5 antibody*Asthma*linerixibat(GSK2330672)IBAT inhibitorCholestatic pruritus in primary biliary cholangitisNucala(mepolizum

3、ab)Anti-IL5 antibodyCOPD1camlipixant(GSK5464714)P2X3 receptor antagonistRefractory chronic coughlatozinemab(GSK4527223)Anti-sortilin antibody*Frontotemporal dementia2Low carbon version of MDI3,Ventolin(salbutamol)Beta 2 adrenergic receptor agonistAsthmaBlenrep(belantamab mafodotin)Anti-BCMA ADC*Mult

4、iple myelomaGSK5764227ADC targeting B7-H3*ES-SCLC4*Jemperli(dostarlimab)Anti-PD-1 antibody*dMMR/MSI-H colon cancer*Zejula(niraparib)PARP inhibitor*Newly diagnosed glioblastoma multiformeArexvy(RSV vaccine)Recombinant protein,adjuvanted*RSV adults(18-49 YoA5 AIR6)*Blujepa(gepotidacin)BTI inhibitor*Un

5、complicated UTI7*bepirovirsen(GSK3228836)Antisense oligonucleotide*Chronic HBV8 infectionBexsero(MenB vaccine)Recombinant protein,OMVMeningitis B(infants US)GSK4178116Live,attenuatedVaricella new seedtebipenem pivoxil(GSK3778712)Antibacterial carbapenem*Complicated UTI74*In-license or other alliance

6、 relationship with third party In registration *Additional indications or candidates also under investigation1.Chronic obstructive pulmonary disease 2.Phase III trial in patients with progranulin gene mutation 3.Metered dose inhaler 4.Extensive-stage small-cell lung cancer 5.Years of age 6.At increa